Leonard Dragone

Chief Tech/Sci/R&D Officer at Abata Therapeutics, Inc.

Health Technology

Consumer Services

Profile

Leonard Dragone is currently the Chief Medical Officer at Abata Therapeutics, Inc. He holds a doctorate degree from The University of California, San Francisco.

Leonard Dragone active positions

Companies	Position	Start
Abata Therapeutics, Inc. Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer.	Chief Tech/Sci/R&D Officer	2023-04-19

All active positions of Leonard Dragone

Training of Leonard Dragone

The University of California, San Francisco

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Leonard Dragone's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Abata Therapeutics, Inc. Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer.	Health Technology